Barclays Has Lowered Expectations for Aspen Aerogels (NYSE:ASPN) Stock Price

Aspen Aerogels (NYSE:ASPN) had its price objective cut by Barclays from $27.00 to $25.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the construction company’s stock. Barclays‘s price objective suggests a potential upside of 60.88% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Roth Mkm decreased their price objective on shares of Aspen Aerogels from $36.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Piper Sandler dropped their price objective on shares of Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Aspen Aerogels in a research note on Wednesday, October 16th. Benchmark reaffirmed a “buy” rating and set a $14.00 price target on shares of Aspen Aerogels in a research note on Thursday, August 8th. Finally, StockNews.com upgraded Aspen Aerogels to a “sell” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.70.

Aspen Aerogels Stock Down 1.6 %

ASPN opened at $15.54 on Tuesday. The company’s 50-day moving average price is $22.66 and its two-hundred day moving average price is $24.74. The company has a quick ratio of 2.82, a current ratio of 2.93 and a debt-to-equity ratio of 0.27. Aspen Aerogels has a twelve month low of $9.57 and a twelve month high of $33.15. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of 1,555.56 and a beta of 2.21.

Insider Buying and Selling at Aspen Aerogels

In related news, CEO Donald R. Young sold 63,355 shares of Aspen Aerogels stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $30.03, for a total value of $1,902,550.65. Following the completion of the transaction, the chief executive officer now owns 483,640 shares in the company, valued at approximately $14,523,709.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the transaction, the chief executive officer now directly owns 483,640 shares in the company, valued at approximately $14,523,709.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $30.14, for a total value of $978,495.10. Following the transaction, the chief financial officer now owns 20,790 shares of the company’s stock, valued at $626,610.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aspen Aerogels

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Aspen Aerogels by 10.1% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 88,714 shares of the construction company’s stock valued at $2,456,000 after buying an additional 8,123 shares during the period. FMR LLC increased its holdings in shares of Aspen Aerogels by 23.6% in the 3rd quarter. FMR LLC now owns 4,050,896 shares of the construction company’s stock valued at $112,169,000 after acquiring an additional 773,647 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Aspen Aerogels by 35.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 35,121 shares of the construction company’s stock valued at $972,000 after acquiring an additional 9,118 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Aspen Aerogels by 22.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,619,320 shares of the construction company’s stock worth $44,839,000 after acquiring an additional 300,076 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in shares of Aspen Aerogels during the 3rd quarter worth $1,342,000. 97.64% of the stock is owned by institutional investors.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.